In addition to conventional lipid-lowering therapies, novel agents such as PCSK9 inhibitors and inclisiran have been shown to exert anti-inflammatory and endothelial-protective effects (48), which could potentially mitigate PSD risk in dyslipidemic stroke survivors. Here, PCSK9 is linked to Stroke.